NHF is thrilled to announce that an additional $200,000 has been raised from individuals and families affected by bleeding disorders, as well as NHF chapters, toward Research is Our Future, NHF’s national campaign advancing our research program. Combined with Novo Nordisk’s previously announced additional gift of $600,000, NHF is within $400,000 of achieving our $1.2 million goal for research support and our ultimate campaign goal of $8.5 million.
Research is our Future Phase II of NHF’s Campaign for Our Future was launched in November 2008. It provides an opportunity for all members of the community to get involved and truly become part of our future by providing the resources needed to improve treatments and accelerate a cure for bleeding disorders.
For more information about the campaign, please contact Mary Ann Ludwig, NHF’s Vice President for Development: 212.328.3741. To learn more about Research is Our Future, or to make a contribution, please visit www.hemophilia.org/campaignforourfuture.
NHF acknowledges all of our 2010 Corporate Partners of the Campaign for our Future: Visionary Corporate Partner and Lead Benefactor Novo Nordisk; Principal Corporate Partner Baxter; Major Corporate Partners Bayer HealthCare, CSL Behring and Pfizer; and Corporate Partner Grifols.